Effect of dressing on exit site infection 4
Moreira et al. [24] and Takei [25] and Barretti et al. [26] have confirmed that mupirocin, applied at nasal mucosa or exit-site as part of regular exit-site care, reduces the risk of S. aureus peritonitis and exit-site infection.
Piraino et al. [27] have showed an overall reduction in the peritonitis rate caused by gram-negative agents from 0.52 to 0.34 episode/year with the use of topical gentamicincream on ES. They have also reported a 63% reduction in the risk of infectious complications due to S. aureus because of the use of mupirocin.
In one randomized, controlled trial Zimmerman et al. [28] have reported a significant decrease in ES infection incidence with administration of oral rifampin, 300 mg PO 2 times/day for the first 5 days of each 12-week interval (0.26 vs. 0.93 catheter infections per patient-year in the control group without treatment). Falagas et al. in a meta-analysis of four randomized studies in hemodialysis or PD patients concluded that the development of S. aureus resistance to rifampin ranging from 0% to 18.2% of patients who treated with oral rifampin. [29] Following studies showed that using these measures in contrast, caused atypical bacterial infection with drug 
